

Bruce Power joins forces with ITM to supply Lutetium-177 for cancer therapy

**Bruce Power to secure global supply of no-carrier-added Lutetium-177 through 2064
ITM to achieve new scalability of n.c.a Lutetium-177 (EndolucinBeta®)**

Tiverton, ON, Canada and Garching, Germany, July 06, 2018 - Bruce Power, a nuclear power company and source of medical radioisotopes, and ITM Isotopen Technologien München (ITM), a specialized radiopharmaceutical group of companies, announced today that ITM's subsidiary, Isotope Technologies Garching (ITG), and Bruce Power have signed an agreement to explore the production of the medical radioisotope no-carrier-added (n.c.a.) Lutetium-177. Lutetium-177 is used in Targeted Radionuclide Therapy to treat cancers like neuroendocrine tumors and prostate cancer. It destroys cancer cells while leaving healthy cells unaffected.

The two companies signed a Memorandum of Understanding to explore the production of n.c.a. Lutetium-177 at the Bruce Power Site. Bruce Power runs commercially operating reactors (CANDU reactors), that allow the company to meet global supply needs of Lutetium-177 through 2064. Furthermore, ITM has developed a unique methodology to produce a special form of Lutetium-177, n.c.a. Lutetium-177, which the company supplies globally under the brand name EndolucinBeta®. Because n.c.a. Lutetium-177 contains no metastable long-lived Lutetium-177m impurities, it provides the highest specific activity of all forms of the Lutetium-177 radioisotope. Its extraordinary level of radionuclidic purity ensures more effective and economical waste management, better environmental sustainability, and the best preconditions for the radiolabeling of biomolecules.

This partnership aims to meet the medical community's growing demand for radionuclides for use in Targeted Radionuclide Therapies. N.c.a. Lutetium-177 will be produced at Bruce Power's CANDU reactors while development, processing, and global distribution of n.c.a. Lutetium-177 will be managed by ITM.

"Bruce Power is a world leader in the production of critical radioisotopes used to treat cancer," said Mike Rencheck, Bruce Power's President and CEO. *"By developing innovative ways to generate these radioisotopes, we help ensure that the medical community has access to a reliable source of medical radioisotopes for Targeted Radionuclide Therapy."*

"We are looking forward to working with Bruce Power to secure a new global supply source and therefore achieve new scalability of our no-carrier-added Lutetium-177," said Steffen Schuster, CEO of ITM. *"With Bruce Power's long-term capacity to operate its facilities through 2064 and its existing expertise with Cobalt production, we have the opportunity to provide a stable, high-quality source of Lutetium-177 to cancer patients worldwide."*

About Bruce Power

Formed in 2001, Bruce Power is an electricity company based in Bruce County, Ontario. We are powered by our people. Our 4,200 employees are the foundation of our accomplishments and are proud of the role they play in safely delivering clean, reliable, low-cost nuclear power to families and businesses across the province. Bruce Power is also a significant source of Cobalt-60, a radioisotope used for the sterilization of medical equipment around the world as well as a specialized form of cancer treatment called the Gamma Knife.

Bruce Power is also part of the newly-established Canadian Nuclear Isotope Council (CNIC), which will ensure Canada remains a world leader in the production of life-saving radioisotopes by raising awareness and supporting long-term policies at the domestic and international level. Over 30 leading organizations from Canada and around the world have joined the council, which will develop collective solutions to maintain Canada's leadership position on the global isotope stage. Learn more at www.brucepower.com and follow us on [Facebook](#), [Twitter](#), [LinkedIn](#), [Instagram](#) and [YouTube](#).

About ITM

ITM Isotopen Technologien München AG is a privately held group of companies dedicated to the development, production and global supply of innovative diagnostic and therapeutic radionuclides and radiopharmaceuticals. Since its foundation in 2004, ITM and its subsidiaries have established GMP manufacturing and a robust global supply network of novel, first-in-class medical radionuclides and generator platform for a new generation of targeted cancer diagnostics and therapies. Furthermore, ITM is developing a proprietary portfolio and growing pipeline of targeted treatments in various stages of clinical development, which address a range of cancers such as neuroendocrine cancers and bone metastases. ITM's main objectives, together with its scientific, medical and industrial collaboration partners worldwide, are to significantly improve outcomes and quality of life for cancer patients while at the same time reducing side-effects and improving health economics through a new generation of Targeted Radionuclide Therapies in Precision Oncology. For more information about ITM, please visit: www.itm.ag

For further information, please contact:

Bruce Power Duty Media:
519-361-6161
BNPDdutymedia@brucepower.com

ITM Contact:
Nicola Scharrer
Head of Marketing
Phone: +49 89 3298986-16
Email: Nicola.Scharrer@itm.ag

ITM Media Contact: WE Communications
Sebastian Klein
Senior Account Executive
Phone: +49 89 628175-46
Email: ITM_AG@we-worldwide.com